| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
HIV/AIDS is a major health concern, it is a global pandemic which remains relatively uncontrolled infectious disease. We independently succeeded in discovering a new lectin, actinohivin (hereafter designate AH), from actinomycete. AH is an excellent candidate for development as an antiretrovial drug to treat or prevent HIV infection.
In order to obtain structural insights into the anti-HIV activity of AH, we crystallized AH and in complex with the target α(1-2)mannobiose (Man2) and α(1-2)(1-2）mannotriose (Man3) moiety of the high-mannose-type glycan (HMTG) attached to HIV-1 gp120. Its crystal structure was successfully solved, revealing that AH is composed of three repeated modules that are closely associated with each other.The present study confirmed that the three mannobiose-binding pockets of AH are almost the same or equivalent and that their tertiary structures are rather rigid.
|
